A  ||| S:0 E:2 ||| DT
proposed  ||| S:2 E:11 ||| JJ
framework  ||| S:11 E:21 ||| NN
to  ||| S:21 E:24 ||| TO
monitor  ||| S:24 E:32 ||| VB
daily  ||| S:32 E:38 ||| JJ
oral  ||| S:38 E:43 ||| JJ
antiretroviral  ||| S:43 E:58 ||| JJ
pre-exposure  ||| S:58 E:71 ||| JJ
prophylaxis  ||| S:71 E:83 ||| NN
in  ||| S:83 E:86 ||| IN
the  ||| S:86 E:90 ||| DT
U.S  ||| S:90 E:95 ||| FW
